Pentadeca Arginate: Complete Evidence and Safety Guide
Medical-review status: A licensed medical reviewer has not yet been assigned to this page. Until one is, the page is published as an editorial draft and is not presented as medically reviewed. See our medical review policy.
Quick answer
Pentadeca Arginate (PDA) is marketed as an arginate-salt form of the peptide BPC-157. We found no peer-reviewed studies of PDA itself. The research people cite is about BPC-157 and is largely animal and laboratory work. PDA is not an FDA-approved drug, its human safety is not established, and BPC-157 is prohibited in sport.
No direct human or animal studies of Pentadeca Arginate were identified; related BPC-157 research is largely preclinical. (No direct study of Pentadeca Arginate was found for this statement.)
| Evidence category | Status | What this means |
|---|---|---|
| Direct PDA human evidence | None identified | No peer-reviewed human clinical trials of Pentadeca Arginate were identified in the reviewed literature. |
| Direct PDA animal evidence | None identified | No peer-reviewed animal studies of the Pentadeca Arginate salt specifically were identified; marketed claims are not published studies. |
| BPC-157 human evidence | Very limited | Human data on BPC-157 are minimal and do not establish effectiveness; BPC-157 is a different, unapproved substance. |
| BPC-157 animal / lab evidence | Preclinical only | Most peptide research is animal or in-vitro work on BPC-157 (e.g., tendon and gastrointestinal models). Preclinical results do not prove human benefit. |
| Mechanistic hypotheses | Proposed, unproven | Proposed mechanisms (e.g., effects on cell migration, angiogenesis, nitric-oxide pathways) are hypotheses from lab work, not demonstrated clinical outcomes. |
| Unknowns | Substantial | PDA’s human pharmacology, effective dose, long-term safety, drug interactions, and whether it behaves like BPC-157 are all unknown. |
| U.S. regulatory status | Not FDA-approved | Neither PDA nor BPC-157 is an FDA-approved drug or a lawful dietary ingredient. BPC-157 is prohibited in sport (WADA class S0). See the FDA-status page. |
Condition directory
Musculoskeletal
Digestive
What Pentadeca Arginate is
Pentadeca Arginate is the marketing name for a peptide sold as an arginate-salt form of BPC-157, a synthetic 15-amino-acid peptide. "Pentadeca" refers to the fifteen amino acids; "arginate" refers to the salt form.
No direct evidence identifiedIt is important to separate what PDA is claimed to be from what has actually been studied. Sellers describe improved stability and absorption, but we found no published human pharmacology supporting those specific claims for the arginate form.
How PDA relates to BPC-157
BPC-157 is the compound with an actual (though preclinical) research base. PDA is presented as a salt variation of it. Related is not the same as equivalent: a salt change can alter solubility, stability, and absorption, and neither has been shown safe and effective in humans.[5]
Keep the forms distinct
Careful reading distinguishes BPC-157 free base, BPC-157 acetate, arginate and other salts, compounded preparations, research-grade materials, and FDA-approved drugs (there are none here).
Evidence at a glance
The table below separates what has been studied directly for PDA from what is extrapolated from BPC-157, and distinguishes human from animal evidence.
Direct PDA research
No direct PDA evidence
No direct evidence identifiedNo direct clinical evidence for Pentadeca Arginate was identified in the reviewed literature. The research discussed below concerns BPC-157 or related preclinical models and should not be interpreted as proof of PDA safety or effectiveness.
Related BPC-157 research
Preclinical evidenceBPC-157 has been studied mainly in animals and cell cultures, with reported effects in tendon and gastrointestinal healing models.[1],[2],[3]
Preclinical evidenceA systematic review of BPC-157 in orthopaedic sports medicine and a recent narrative review both conclude the human evidence is minimal and the risk–benefit balance is unresolved.[4],[5]
Human versus animal evidence
Preclinical evidenceAlmost all peptide findings here come from animals or cells. Most compounds that look promising in animals do not go on to prove safe and effective in human trials. Treating animal results as human proof is a common and serious error.
Potential applications being researched
The areas most discussed in the BPC-157 literature are musculoskeletal healing, digestive-tract protection, and pain and inflammation. In every case, the human evidence for PDA is absent and the BPC-157 evidence is preclinical.
- Musculoskeletal: tendon, ligament, and muscle healing models (preclinical).
- Digestive: animal models of stomach and intestinal injury (preclinical).
- Pain and inflammation: proposed effects from laboratory work (mechanistic).
Evidence limitations
- No published clinical trials of Pentadeca Arginate for any condition.
- No published human pharmacology for the arginate salt form.
- The BPC-157 base is largely animal and laboratory work.
- Marketing claims and testimonials are not evidence.
Safety concerns
Limited human evidencePDA’s human safety is not established. U.S. authorities describe BPC-157 as an unapproved drug that is not a lawful dietary ingredient, and note quality and safety risks with compounded or "research-use-only" peptides, including immunogenicity and impurities.[8],[7]
Possible side effects
Because PDA has not been formally studied in humans, its side-effect profile is unknown. Unknown is not the same as safe. See the dedicated side-effects page for detail.
Possible interactions
Interactions with medications, supplements, and medical conditions are unknown. People who are pregnant or breastfeeding, or who have cancer, clotting disorders, or other serious conditions, should be especially cautious. Tell your clinician and pharmacist about everything you take.
Regulatory status
Neither PDA nor BPC-157 is an FDA-approved drug. Based on FDA materials reviewed on July 22, 2026, BPC-157 has a complex compounding history and remains outside the approved-drug and lawful-supplement pathways. This describes the federal record and is not legal advice.[6],[7]
Athletic and anti-doping considerations
BPC-157 is on the World Anti-Doping Agency Prohibited List (class S0, non-approved substances). PDA’s status can differ and can change. FDA status and anti-doping status are different questions, and a clinician’s recommendation does not make a prohibited substance permissible in competition. Athletes must verify substances through current USADA/WADA resources.[8]
Questions to ask a licensed clinician
- What human evidence exists that PDA helps my condition? (Currently, none was identified.)
- What proven treatments should I try first?
- What are the risks given my health and medications?
- Could this cause an anti-doping violation?
Condition directory
Explore plain-language, evidence-graded pages on the conditions where PDA and BPC-157 are discussed. Each keeps established medical care separate from experimental peptide claims.
Frequently asked questions
Is Pentadeca Arginate FDA-approved?
No. Neither PDA nor BPC-157 is an FDA-approved drug. See the PDA regulatory-status page for detail.
Does PDA work?
There is no human evidence that PDA works for any condition. Claims are extrapolated from preclinical BPC-157 research.
Is PDA the same as BPC-157?
PDA is marketed as an arginate-salt form of BPC-157, but the two are not proven equivalent, and PDA has no studies of its own.
Is PDA safe?
Its human safety is not established, and unapproved peptides carry documented quality and safety concerns.
References
5 peer-reviewed journal sources and 3 additional authoritative references. Every reference supports a specific statement above.
- [1] Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2):153–159. View source Peer-reviewed journal
- [2] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3):774–780. View source Peer-reviewed journal
- [3] Sikirić P, Seiwerth S, Rucman R, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16):1612–1632. View source Peer-reviewed journal
- [4] Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal (SAGE), Systematic review. View source Peer-reviewed journal
- [5] Current Reviews in Musculoskeletal Medicine (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, Narrative review. View source Peer-reviewed journal
- [6] U.S. Food and Drug Administration (2025). Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA.gov, Regulatory information (compounding). View source Government / regulatory
- [7] U.S. Food and Drug Administration (2025). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA.gov, Regulatory information (compounding safety). View source Government / regulatory
- [8] Operation Supplement Safety (U.S. Department of Defense) (2024). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. OPSS.org (DoD), U.S. government consumer-safety advisory. View source Government / regulatory